Kidney Injury Associated with Telavancin Dosing Regimen in an Animal Model

ABSTRACT The elevation of serum creatinine levels is a concern with telavancin therapy. We examined the onset of kidney injury associated with telavancin in an animal model. Urine samples were collected at baseline and daily to determine the concentrations of kidney injury molecule 1 (KIM-1), a marker for early kidney injury. When a clinically relevant exposure of telavancin was given daily to rats, some differences in kidney injury were attributed to the dosing regimen. Further investigations of alternative telavancin dosing regimens are warranted.

[1]  V. Tam,et al.  Pharmacokinetics and Renal Disposition of Polymyxin B in an Animal Model , 2012, Antimicrobial Agents and Chemotherapy.

[2]  Ming Hu,et al.  Characterization of Polymyxin B-Induced Nephrotoxicity: Implications for Dosing Regimen Design , 2012, Antimicrobial Agents and Chemotherapy.

[3]  S. Czasch,et al.  Evaluation of Novel Acute Urinary Rat Kidney Toxicity Biomarker for Subacute Toxicity Studies in Preclinical Trials , 2012, Toxicologic pathology.

[4]  M. Niederman,et al.  Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  G. Stein,et al.  Telavancin: a novel lipoglycopeptide. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  V. Tam,et al.  Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. , 2009, International journal of antimicrobial agents.

[7]  V. Fowler,et al.  Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  J. Shaw,et al.  Intrapulmonary Distribution of Intravenous Telavancin in Healthy Subjects and Effect of Pulmonary Surfactant on In Vitro Activities of Telavancin and Other Antibiotics , 2007, Antimicrobial Agents and Chemotherapy.

[9]  J. Shaw,et al.  Pharmacodynamics of Telavancin (TD-6424), a Novel Bactericidal Agent, against Gram-Positive Bacteria , 2004, Antimicrobial Agents and Chemotherapy.

[10]  P. Francioli,et al.  Simulated human serum profiles of one daily dose of ceftriaxone plus netilmicin in treatment of experimental streptococcal endocarditis , 1993, Antimicrobial Agents and Chemotherapy.